Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.
Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patiño A, Arrieta O, Hakim EJ, Hakim F, Mejía JA, Useche N, Bermúdez S, Carranza H, Vargas C, Otero J, Mayor LC, Ortíz LD, Franco S, Ortíz C, Gil-Gil M, Balaña C, Zatarain-Barrón ZL. Cardona AF, et al. Among authors: ortiz ld. J Neurooncol. 2018 Jan;136(2):363-371. doi: 10.1007/s11060-017-2660-0. Epub 2017 Nov 25. J Neurooncol. 2018. PMID: 29177594
Genotyping low-grade gliomas among Hispanics.
Cardona AF, Rojas L, Wills B, Behaine J, Jiménez E, Hakim F, Useche N, Bermúdez S, Arrieta O, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, González D, Rodríguez J, Ortiz LD, Cifuentes H, Balaña C. Cardona AF, et al. Among authors: ortiz ld. Neurooncol Pract. 2016 Sep;3(3):164-172. doi: 10.1093/nop/npv061. Epub 2016 Jan 28. Neurooncol Pract. 2016. PMID: 31386063 Free PMC article.
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O. Cardona AF, et al. Among authors: ortiz ld. Clin Transl Oncol. 2019 Oct;21(10):1364-1373. doi: 10.1007/s12094-019-02066-2. Epub 2019 Feb 23. Clin Transl Oncol. 2019. PMID: 30798512
Stem cells in brain tumorigenesis and their impact on therapy.
Cardona AF, Balañá C, Torres D, Becerra H, Ortíz LD, Fadul CE. Cardona AF, et al. Among authors: ortiz ld. Curr Stem Cell Res Ther. 2011 Dec;6(4):339-49. doi: 10.2174/157488811797904317. Curr Stem Cell Res Ther. 2011. PMID: 21466481 Review.
Anti-VEGF therapy in pituitary carcinoma.
Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K. Ortiz LD, et al. Pituitary. 2012 Sep;15(3):445-9. doi: 10.1007/s11102-011-0346-8. Pituitary. 2012. PMID: 21918831
Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K. Ortiz LD, et al. Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):119-23. doi: 10.6061/clinics/2012(sup01)20. Clinics (Sao Paulo). 2012. PMID: 22584716 Free PMC article. Review.
27 results